Siren, L.L.C. Ascendis Pharma A/S Transaction History

Siren, L.L.C.

$2 Trillion
Q3 2024

A detailed history of Siren, L.L.C. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Siren, L.L.C. holds 347,921 shares of ASND stock, worth $43.8 Million. This represents 2.6% of its overall portfolio holdings.

Number of Shares

347,921

Holding current value

$43.8 Million

% of portfolio

2.6%

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 13, 2024	BUY	$113.0 - $153.43 $39.3 Million - $53.4 Million	347,921 New	347,921 $51.9 Billion

Others Institutions Holding ASND

# of Institutions

227

Shares Held

56.4M

Call Options Held

125K

Put Options Held

239K

Ra Capital Management, L.P. Boston, MA

10.1M
Shares

$1.27 Billion
20.78% of portfolio
Westfield Capital Management CO LP Boston, MA

5.13M
Shares

$647 Million
3.62% of portfolio
Avoro Capital Advisors LLC New York, NY

4.99M
Shares

$629 Million
11.21% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

4.41M
Shares

$556 Million
1.03% of portfolio
Janus Henderson Group PLC London, X0

4.19M
Shares

$528 Million
0.33% of portfolio

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.03B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Siren, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Siren, L.L.C. with notifications on news.

Account